View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 3, 2021updated 11 Jul 2022 9:50am

Sorrento initiates enrolment for Phase II Covid-19 drug trial in Brazil

The trial will analyse the efficacy and safety of three doses of COVI-MSC plus standard of care treatment in 100 patients.

Sorrento Therapeutics has begun subject enrolment in Phase II clinical trial of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) in Covid-19 patients with acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) in Brazil.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The first subject was enrolled at the first centre of the Phase II trial in the country.

The second centre is anticipated to commence patient enrolment in a week, with various other centres to be launched in a month.

Mesenchymal stem cells were showed to aid in symptom resolution in various disease settings and can potentially decrease the lasting effects linked to pulmonary tissue damage.

Named ‘MSC-COV-202BR’, the multi-arm, randomised, placebo-controlled Phase II trial will assess the efficacy and safety of three infusions of COVI-MSC given on different schedules along with the standard of care Covid-19 therapies.

It will enrol 100 subjects, with the efficacy of COVI-MSCs being the primary goal.

In addition, Sorrento intends to commence enrolment in two more Phase II trials of COVI-MSC.

The parallel, placebo-controlled Phase II safety trial will be carried out at various centres in the US while another Phase II safety and efficacy trial for pulmonary long hauler will be conducted at various sites in Brazil.

Sorrento Therapeutics chairman and CEO Dr Henry Ji said: “It brings us great pleasure to see our MSC treatments for Covid-19-induced ARD/ARDS and post-Covid pulmonary long-haul syndrome rapidly move forward in clinical trials and towards a potential emergency approval of this promising therapy globally.

“We believe that COVI-MSC can help save lives, which is our primary goal at Sorrento.”

A clinical and commercial-stage biopharmaceutical firm, Sorrento focuses on developing novel treatments for cancer, autoimmune disease and Covid-19, as well as non-opioid therapies for pain.

Last month, Sorrento reported that the protein-based Covid-19 vaccine candidate, DYAI-100, induced robust neutralising B-cell immune responses against the original SARS-CoV-2 strain and emerging variants, such as Beta and Delta, in preclinical studies.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology